You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
Title |
Tissue Agnostic Activity of BRAF plus MEK inhibitor in BRAF V600 mutant tumorsBRAF in nonmelanoma cancers
|
---|---|
Published in |
Molecular Cancer Therapeutics, April 2022
|
DOI | 10.1158/1535-7163.mct-21-0950 |
Pubmed ID | |
Authors |
Jacob J. Adashek, Arjun K. Menta, Neha K. Reddy, Aakash P. Desai, Jason Roszik, Vivek Subbiah |
X Demographics
The data shown below were collected from the profiles of 117 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 29 | 25% |
Mexico | 5 | 4% |
India | 5 | 4% |
France | 5 | 4% |
Turkey | 4 | 3% |
Brazil | 3 | 3% |
Spain | 3 | 3% |
Colombia | 3 | 3% |
Germany | 2 | 2% |
Other | 11 | 9% |
Unknown | 47 | 40% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 61 | 52% |
Scientists | 26 | 22% |
Practitioners (doctors, other healthcare professionals) | 19 | 16% |
Science communicators (journalists, bloggers, editors) | 10 | 9% |
Unknown | 1 | <1% |
Mendeley readers
The data shown below were compiled from readership statistics for 20 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 20 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Unspecified | 3 | 15% |
Researcher | 3 | 15% |
Student > Postgraduate | 2 | 10% |
Student > Master | 2 | 10% |
Student > Doctoral Student | 1 | 5% |
Other | 4 | 20% |
Unknown | 5 | 25% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 10 | 50% |
Unspecified | 3 | 15% |
Biochemistry, Genetics and Molecular Biology | 2 | 10% |
Unknown | 5 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 61. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 19 April 2023.
All research outputs
#697,682
of 25,401,381 outputs
Outputs from Molecular Cancer Therapeutics
#76
of 4,067 outputs
Outputs of similar age
#17,931
of 447,475 outputs
Outputs of similar age from Molecular Cancer Therapeutics
#3
of 57 outputs
Altmetric has tracked 25,401,381 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,067 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.8. This one has done particularly well, scoring higher than 98% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 447,475 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 57 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.